PCSK9 Inhibitor, EGF-A

PCSK9 Inhibitor, EGF-A is a PCSK9 inhibitor. PCSK9 Inhibitor, EGF-A is residues 293-334 of the EGF-A domain of the low-density lipoprotein (LDL) receptor. PCSK9 Inhibitor, EGF-A can prevent PCSK9-induced intracellular LDLR degradation. PCSK9 Inhibitor, EGF-A can be used in the study of hypercholesterolemia and premature atherosclerosis[1].

Product Specifications

UNSPSC

12352209

Target

PCSK9

Related Pathways

Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Smiles

O=C(CN)N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H]1C(C)C)=O)CC2=CNC=N2)=O)CO)=O)CSSC[C@H](NC3=O)C(N[C@H](C(N[C@H](C(N4[C@H](C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H]5CCCNC(N)=N)=O)CCCNC(N)=N)=O)CCC(N)=O)=O)C)=O)C(C)C)=O)CC(C)C)=O)CCC(N)=O)=O)CC6=CC=CC=C6)=O)=O)CC(O)=O)=O)CCC4)=O)CSSC[C@H](NC5=O)C(N[C@H](C(N[C@H](C(N[C@H](C(N)=O)[C@H](CC)C)=O)CC(O)=O)=O)CCC(O)=O)=O)=O)CC(C)C)=O)=O)=O)=O)CC(N)=O)=O)CC(N)=O)=O)CC(O)=O)=O)CC(C)C)=O)CSSC[C@H](NC1=O)C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N[C@H]3CCC(O)=O)=O)CC7=CC=C(O)C=C7)=O)=O)[C@H](CC)C)=O)CCCCN)=O)CC(C)C)=O)CC(O)=O)=O)CC(N)=O)=O)=O)CCC(O)=O)=O)CC(N)=O)=O)[C@@H](C)O

Molecular Formula

C188H292N58O65S6

Molecular Weight

4597.07

References & Citations

[1]Zhang DW, et al. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem. 2007 Jun 22;282 (25) :18602-18612.